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Abstract
A sizable body of research has now examined the complex relationship between quality of life
(QoL) and depressive disorder. Uptake of QoL research in relation to bipolar disorder (BD) has
been comparatively slow, although increasing numbers of QoL studies are now being conducted in
bipolar populations. We aimed to perform a review of studies addressing the assessment of generic
and health-related QoL in patients with bipolar disorder.
A literature search was conducted in a comprehensive selection of databases including MEDLINE
up to November 2004. Key words included: bipolar disorder or manic-depression, mania, bipolar
depression, bipolar spectrum and variants AND quality of life, health-related QoL, functional status,
well-being and variants. Articles were included if they were published in English and reported on
an assessment of generic or health-related QoL in patients with BD. Articles were not included if
they had assessed fewer than 10 patients with BD, were only published in abstract form or only
assessed single dimensions of functioning.
The literature search initially yielded 790 articles or abstracts. Of these, 762 did not meet our
inclusion criteria, leaving a final total of 28 articles. These were sub-divided into four categories
(assessment of QoL in patients with BD at different stages of the disorder, comparisons of QoL in
Patients with BD with that of other patient populations, QoL instrument evaluation in patients with
BD and treatment studies using QoL instruments to assess outcome in Patients with BD) and
described in detail.
The review indicated that there is growing interest in QoL research in bipolar populations.
Although the scientific quality of the research identified was variable, increasing numbers of studies
of good design are being conducted. The majority of the studies we identified indicated that QoL
is markedly impaired in patients with BD, even when they are considered to be clinically euthymic.
We identified several important avenues for future research, including a need for more assessment
of QoL in hypo/manic patients, more longitudinal research and the development of a disease-
specific measure of QoL for patients with BD.
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Review
Good quality of life (QoL) encompasses more than just
good health. At a basic level, it can represent the sum of a
person's physical, emotional, social, occupational and
spiritual well-being, the study of which is complicated by
the fact that there is no consensus as to what constitutes
QoL. The World Health Organization has described QoL
as "individuals' perception of their position in life in the
context of the culture and value systems in which they live
and in relation to their goals, expectations, standards and
concerns" [1]. This broad, generic conceptualization of
QoL can be distinguished from the more specific concept
of 'health-related quality of life' (HRQOL), which refers to
those aspects of an individual's life that impact directly
upon their health [2] and the more economically-derived
'cost-utility' models of QoL. This area of research is further
complicated by the understanding that QoL can be highly
subjective, potentially fluid and open to distortion, mak-
ing it challenging to measure reliably and accurately. Yet,
there is a growing body of evidence to suggest that QoL is
an important indicator of well-being, and one that we
should be attempting to capture when assessing the
patient health.
The assessment of QoL in medical settings may be of value
in several ways. QoL instruments can provide levels of
information not always supplied by traditional outcome
measures. For example, some instruments such as the
Schedule for the Evaluation of Individualized Quality of
Life (SEIQoL) [3] and the Patient Generated Index [4]
allow patients to prioritize which life domains are most
important to them. While the reduction of symptoms may
be the primary goal of the clinician, it may be that the
patient places more emphasis upon restoring family rela-
tionships, or being able to engage in leisure activities.
These 'individualized' measures, although sometimes dif-
ficult to administer and interpret, put the patient at the
centre rather than at the periphery of assessing the effec-
tiveness of treatment interventions. QoL assessments can
also help determine patient preference, allow compari-
sons of well-being between different conditions and
detect subtle differences in response to treatment that may
be missed by traditional outcome measures.
While a host of studies have now examined QoL in
patients with major depressive disorder (MDD) (for
example, [5-8] until recently few had specifically focused
upon QoL in patients with bipolar disorder (BD). The
slow uptake of QoL research in BD may have occurred in
part because of the absence of a 'disease-specific' measure
of QoL for bipolar populations, or because of reservations
about the ability of patients with BD to reliably and accu-
rately complete self-report measures, particularly when in
a manic phase.
Two reviews of previous research addressing health-
related QoL (HRQOL) in BD have been conducted [9,10].
In the first of these, Namjoshi and colleagues (1999)
assessed all relevant English-language articles published
prior to 1999, identifying 10 studies for inclusion. The
studies proved to be quite heterogeneous, and used a vari-
ety of generic and depression-specific instruments to
assess different aspects of HRQOL. They also tended to be
relatively small (only one study had a sample size in
excess of 100 patients), were conducted in depressed or
euthymic (rather than hypo/manic) patients, and rarely
included descriptions of the psychometric properties of
the instruments they utilized. The authors of the review
made a number of suggestions for future research, includ-
ing the development of a disease-targeted measure of QoL
for BD, more assessments in acutely manic patients, and
more longitudinal research. The second review conducted
by Dean and colleagues (2004) examined studies that had
assessed HRQOL, work-impairment or healthcare costs
and utilization in patients with BD published prior to
November 2002. The review applied a very broad defini-
tion of HRQOL, including in this category studies that
had assessed social or physical functioning in isolation
(for example, the Global Assessment of Functioning or
GAF scale was included as a measure of HRQOL). Using
this broad definition, the review identified 65 HRQOL
articles. The authors concluded that deficits in HRQOL in
patients with BD are similar to those observed in patients
with unipolar depression and equal or lower than levels of
HRQOL observed in patients with other chronic medical
conditions.
Given the recent upsurge of interest in describing QoL in
BD, the present study aimed to provide an updated litera-
ture review of studies that have assessed both generic and
HRQOL in patients with bipolar disorder.
Materials and methods
A comprehensive literature search (supplemented by
hand searching where appropriate) was conducted in the
following databases up to November 2004:
MEDLINE (1966–2004)
EMBASE (the Excerptra Medica database) (1988–2004)
PubMed (1967–2004)
PsychINFO (1967–2004)
CINAHL (Cumulated Index to Nursing and Allied Health
Literature) (1982–2004)
American College of Physicians Journal Club (1991–
2004)Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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Flowchart of review results Figure 1
Flowchart of review results.
A total of 790 potentially relevant
reports were initially identified via
literature and hand searching
(conducted up to November 2004)
110 articles were
obtained for further
evaluation
A further 82 articles were rejected after
further examination.  The authors of 15
papers were unable to provide separate
QoL results for patients with BD from
studies that had used heterogeneous
patient populations
77 articles excluded as
they were not written
in English/no abstract
was available
The abstracts of 713
articles were retrieved for
more detailed evaluation.
603 articles were rejected as they met one
or more of the review’s exclusion criteria
(i.e. did not assess multiple domains of
QoL, examined fewer than 10 patients
with BD, were not published in a peer-
reviewed journal)
28 studies were finally included in
the review, and were classified into
four categories
Assessment of QoL in patients
with BD at different stages of
the disorder (N=10)
Comparisons of QoL in BD
patients with that of other
patient populations (N=5)
QoL instrument evaluation in
BD patients (N=5)
Treatment studies using QoL
instruments to assess outcome
in BD patients (N=8)Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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Table 1: Summary of studies assessing quality of life in patients with bipolar disorder
Study Location Population(s) QoL instrument(s) Main findings and limitations
Arnold et al., (2002) US 44 BD patients (38 type I, 5 
type II, I NOS)
30 back pain patients 
2474 general population
SF-36 HRQOL impaired in BD patients compared to 
non-clinical sample. Chronic back pain patients 
more impaired in all SF-36 domains except role 
limitation (emotional) and mental health.
Limitation – disparate sample sizes.
Atkinson et al., (1997) Canada 37 BD patients
69 patients with 
schizophrenia
35 MDD patients
QoL index BD and MDD patients subjectively reported 
lower QoL than patients with schizophrenia, but 
schizophrenia group had poorer objectively 
measured QoL.
Limitation – relatively small BD and MDD 
sample sizes.
Bond et al., (2000) US 149 patients with SMI (21 
with BD)
QOLI Mean overall life satisfaction QOLI scores 
showed mid-range impairment.
Limitation – small sample of patients with BD.
Chand et al., (2004) India 50 BD patients in remission
20 patients with 
schizophrenia
20 control subjects
Q-LES-Q, WHO-QOL-
BREF
Patients with BD generally reported better QoL 
than patients with schizophrenia, and equivalent 
QoL to control group subjects.
Limitation – incomplete matching between 
groups; unusually low Q-LES-Q scores in 
control group
Cooke et al., (1996)* Canada 68 euthymic BD patients 
(55 type I, 13 type II)
SF-20 SF-20 scores comparable to those reported for 
patients with MDD. BD type II patients 
reported poorer HRQOL that BD type I.
Limitation – shortcomings of SF-20 compared to 
SF-36.
Dogan et al., (2003) Turkey 26 outpatients with BD 
stabilized on lithium
WHO-QOL-BREF Significant improvement in general health, 
physical functioning and social functioning 3 
months after a psychoeducation intervention.
Limitation – small sample size.
Kusznir et al., (2000) Canada 61 euthymic BD patients 
(47 type I, 14 type II)
OPQ One third of sample did not meet criteria for 
adequate community functioning.
Limitation – cross-sectional research design.
Leidy et al., (1998) US 62 BD patients, type I (34 
euthymic, 28 depressed)
SF-36, QLDS, MHI-17 
and CFS
Psychometric properties of instruments 
generally in acceptable ranges. Marked 
impairment in SF-36 scores apparent and QLDS 
scores lower than reported elsewhere for 
patients with unipolar MDD.
Limitation – test-retest reliability was measured 
over an unusually long period.
MacQueen et al., 
(1997)
Canada 62 euthymic BD patients, 
type I
SF-20 No significant differences in SF-20 scores 
between psychotic and non-psychotic patients.
Limitation – small sample of patients with 
psychotic symptoms.
MacQueen et al., 
(2000)
Canada 64 euthymic BD patients, 
type I
SF-20 Number of previous depressive episodes a 
stronger determinant of HRQOL than number 
of previous manic episodes.
Limitation – number of previous episodes 
determined retrospectively.
Namjoshi et al., 
(2002)
US 139 BD patients, type I SF-36 Acute treatment with olanzapine resulted in 
improved SF-36 physical functioning scores; 
improvement in vitality, pain, general health and 
social functioning domains apparent in open-
label phase.
Limitation – adjunctive use of lithium and 
fluoxetine during open-label phase.
Namjoshi et al., 
(2004)
US 224 BD patients, type I QOLI Olanzapine cotherapy associated with better 
outcome in several QOLI domains compared to 
monotherapy with lithium or valproate.
Limitation – only acute QoL outcome data 
available.
Olusina et al., (2003) Nigeria 25 outpatients with BD 
type I or II
WHO-QOL-BREF-TR Majority of sample report 'fair/average' QoL. 
Small sample of patients with BD, little clinical 
information for sample.Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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Ozer et al., (2002) Turkey 100 interepisode BD 
patients
Q-LES-Q Depression scores on SADS interview 
significantly predicted lower Q-LES-Q scores.
Limitation – cross-sectional nature of research.
Patelis-Siotis et al., 
(2001)
Canada 49 BD mildly depressed or 
euthymic patients
SF-36 SF-36 vitality and role (emotional) scores 
significantly improved after CBT.
Limitation – Open study, and SF-36 scores only 
available for a sub-set of patients.
Perlis et al., (2004) US 983 patients with BD type 
I, II or NOS
Q-LES-Q Younger age of onset of BD predicts Q-LES-Q 
scores.
Revicki et al., (1997) US 28 outpatients diagnosed 
with DSM-III-R BD
SF-36 Onset of BD determined retrospectively.
No significant differences in SF-36 domain 
scores according to mode of administration (in-
person vs. telephone).
Limitation – small sample size.
Revicki et al., (2003) US 120 BD type I patients 
hospitalized for acute 
mania
Q-LES-Q No differential effects of treatment with 
divalproex sodium vs. olanzapine on QoL
Limitation – only 43% of randomized patients 
completed Q-LES-Q
Ritsner et al., (2002) Israel 17 BD patients (9 manic, 4 
depressed, 4 mixed)
Q-LES-Q and LQOLP Q-LES-Q scores poorest in depressed patients, 
highest in manic.
Limitation – small sample of patients diagnosed 
with BD.
Robb et al., (1997)* Canada 68 euthymic BD patients 
(55 type I, 13 type II)
IIRS Greater illness intrusiveness associated with 
higher Ham-D scores, recent depression and 
BD type II.
Limitation – IIRS not validated for use in BD 
populations.
Robb et al., (1998)* Canada 69 euthymic BD patients 
(54 type I, 15 type II)
SF-20 Women possessed significantly lower SF-20 
scores in the domains of pain and physical 
health.
Limitation – shortcomings of SF-20 as a HRQOL 
measure.
Russo et al., (1997) US 241 BD inpatients (138 
depressed, 103 manic)
QOLI Manic BD patients reported better QoL than 
BD depressed patients.
Limitation – lower response rate in acutely 
manic group.
Ruggeri et al., (2002) Italy 22 BD patients LQOLP LQOLP mean scores similar to those observed 
in larger mixed sample of psychiatric patients.
Limitation – small sample of bipolar patients.
Salyers et al., (2000) US 164 BD patients SF-12 Mental health scores significantly lower in 
patients with unipolar depression.
Limitation – brief nature of SF-12.
Shi et al., (2002) Europe US, 
South 
America 
South Africa
453 BD patients, type I SF-36 Olanzapine superior to haloperidol in improving 
HRQOL during acute and continuation 
treatment in most SF-36 domains.
Limitation – relatively high drop-out rates 
during acute treatment phase.
Shi et al., (2004) 7 countries 573 BD in/outpatients, type 
I, most recent episode 
depressed
SF-36, QLDS Olanzapine-fluoxetine combination associated 
with grater improvement in HRQOL.
Limitation – high drop-out rate for an 8-week 
trial (55%).
ten Have et al., (2002) Netherlands 136 BD patients (93 type I, 
43 NOS)
SF-36 BD sample generally showed greater 
impairment in SF-36 scores than patients with 
other psychiatric diagnoses.
Limitation – accuracy of CIDI diagnosis of BD 
NOS in question.
Tsevat et al., (2000) US 53 BD patients SF-36, TTO and SG TTO (0.61) and SG (0.70) scores for mental 
health comparable to those reported for other 
psychiatric conditions.
Limitation – cognitive complexity of TTO and 
SG tasks.
Vojta et al., (2001) US 86 BD patients (16 manic/
hypomanic, 26 MDD, 14 
mixed, 30 euthymic)
SF-12 and EuroQoL SF-12 mental health scores significantly lower in 
manic group than in euthymic group. MDD/
mixed group SF-12 scores significantly poorer 
than in manic/euthymic groups.
Limitation – small sub-samples, brief nature of 
the SF-12.
Table 1: Summary of studies assessing quality of life in patients with bipolar disorder (Continued)Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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Wells et al., (1999) US 331 BD patients 944 
double depression 3479 
MDD 151 dysthymia 987 
depressive symptoms
SF-12, TTO and SG BD group had lower health utility than MDD, 
dysthymia and depressive symptoms groups.
Limitation – cognitive complexity of TTO and 
SG tasks.
Yatham et al., (2004) 15 countries 920 BD type I patients 
(currently depressed/
experienced episode of 
depression in previous 60 
days)
SF-36 SF-36 scores markedly impaired compared to 
general population norms and consistently 
lower than sub-scale scores for patients with 
unipolar MDD.
Limitation – depression severity not controlled 
for.
* counted as one study for purposes of review
EuroQoL visual analog scale
Illness Intrusiveness Rating Scale
Lancashire Quality of Life Profile
Lehman Quality of Life Interview
Longitudinal Interval Follow-up Evaluation
Mental Health Index 17
MOS Cognitive Function Scale
MOS Short Form 12
MOS Short Form 20
MOS Short Form 36
Occupational Performance Questionnaire
Quality of Life Enjoyment and Satisfaction Questionnaire
Quality of Life in Depression Scale
Quality of Life Index
Quality of Life Interview
Severe Mental Illness
Standard gamble
Time tradeoff
World Health Organization Quality of Life Assessment
Table 1: Summary of studies assessing quality of life in patients with bipolar disorder (Continued)
CDSR (Cochrane Database of Systematic Reviews) (-
2004)
CCTR (Cochrane Controlled Trials Register) (-2004)
DARE (Database of Abstracts of Reviews of Effectiveness)
IPA (International Pharmaceutical Abstracts) (1965–
2004)
Key words used for the search included: bipolar disorder
or manic-depression, mania, bipolar depression, bipolar
spectrum and variants AND quality of life, health-related
QoL, functional status, well-being and variants. Articles
were included if they were published in the English lan-
guage, and reported on the assessment of generic or
HRQOL in patients with BD. Our definition of QoL was
not overly-inclusive; we required that studies had used a
QoL or HRQOL scale that assessed several domains of
functioning. Studies using scales that examined single
domains of QoL (for example, those assessing solely
social or occupational functioning, or single-item scales
such as the GAF) were excluded. We omitted studies that
included fewer than 10 patients with BD, but did not
reject reports for other scientific limitations (for example,
convenience sampling or cross-sectional designs). Studies
that were underway but were not completed were
excluded, as were conference abstracts, dissertations or
reports on QoL in BD that were not published in peer-
reviewed journals. We also excluded studies that reported
assessments in groups of patients with heterogeneous
diagnoses where results for patients with BD were not
reported separately, and where individual results this pop-
ulation could not be provided by the authors after per-
sonal communication (for example, [11-25].
Results
The results of the literature search are summarized
QUOROM-style in Figure 1. The final 28 included articles
are summarized in Table 1.
Review of studies
This section will review the 28 studies we identified. For
ease of interpretation they are classified into the following
four categories, although several studies met criteria for
more than one category.
i) Assessment of QoL in patients with BD at different
stages of the disorder
ii) Comparisons of QoL in patients with BD with that of
other patient populations
iii) QoL instrument evaluation in patients with BD
iv) Treatment studies using QoL instruments to assess out-
come in patients with BDHealth and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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i) Assessment of QoL in patients with BD at different stages of the 
disorder
We identified ten studies of QoL in patients with BD at
different stages of the disorder. Four of these were gener-
ated by a research group in Canada, and will be dealt with
in unison. Following this, six other studies (one compar-
ing QoL in patients with during different phases of the
disorder, a recent study assessing QoL in bipolar depres-
sion, one performed in a Turkish sample of interepisode
patients, one conducted in a sample of patients attending
a mental health service in Italy, one in recently discharged
patients in Nigeria and a report on patients enrolled in the
STEP-BD Program) will be described.
A research group in Toronto, Canada has generated a
series of interrelated reports on QoL in BD. Three of the
series [26-28] describe various aspects of QoL in a single
sample of outpatients (N = ~68) with BD type I (with
manic episodes) or II (with hypomanic episodes) who
had been clinically euthymic for at least one month (these
have been counted as one study for the purposes of this
review). Three of the series report on QoL in other patient
populations [29-31]. Cooke and colleagues [26] exam-
ined levels of HRQOL using the MOS SF-20, [32] a self-
report questionnaire designed to assess perceived well-
being in six domains (physical, social and role function-
ing, mental health status, health perceptions and bodily
pain). Mean scores on the SF-20 domains in study
patients were comparable to those reported for patients
with MDD by Wells and colleagues in the large RAND
Corporation MOS Study [33]. Analysis of SF-20 scores by
type of BD showed that patients with BD type II reported
significantly poorer HRQOL than BD type I in the areas of
social functioning and mental health. In another paper,
Robb and colleagues [27] reported on functioning in the
context of the 'Illness Intrusiveness Model' in patients
with BD [34,35]. The model addresses the impact a disor-
der and/or its treatment has upon an individual's activi-
ties across 13 life domains: health, diet, active/passive
recreation, work/financial status, self expression/improve-
ment, family relations, relations with spouse, sex life,
other relationships, religious expression and community
involvement. The Illness Intrusiveness Rating Scale (IIRS)
is used to yield a 'total illness intrusiveness' (TII) score. Ill-
ness intrusiveness occurred in several areas of functioning,
with TII being associated with higher Hamilton Depres-
sion Rating Scale (Ham-D) scores, patients having experi-
enced a recent episode of depression and having type II
BD. Robb and colleagues [28] specifically focused upon
gender differences in SF-20 scores, finding that women
possessed numerically lower scores in all of the question-
naire's domains except for mental health, with significant
differences in the domains of pain and physical health.
Interestingly, objective measures of functioning (clinician
rated Global Assessment of Functioning or GAF scores)
were not significantly different by gender.
MacQueen and colleagues [29] examined SF-20 scores in
euthymic BD type I patients (N = 62) with or without psy-
chotic symptoms during an index episode of mania. No
significant differences in SF-20 scores were apparent
between patients with or without psychosis, although the
sample identified with psychosis may have been too small
(N = 16) to detect statistically significant differences
between sub-groups. Kusznir and colleagues [30] assessed
levels of community functioning via the Occupational
Performance Questionnaire (OPQ) in a similar popula-
tion, finding that one-third of patients did not meet crite-
ria for adequate functioning on the 'Community
Functioning Scale' component of the questionnaire.
Finally, MacQueen and colleagues [31] focused upon the
effect of number of manic and depressive episodes on SF-
20 and GAF scores in euthymic patients (N = 64), finding
that number of past episodes of depression was a stronger
determinant of HRQOL than number of previous manic
episodes. Good correlation between the subjectively rated
SF-20 and objectively rated GAF scores provided some evi-
dence that euthymic patients with BD are capable of pro-
viding accurate descriptions of their HRQOL.
A potential advantage of this series of studies is that the
majority of them were conducted in euthymic outpa-
tients; interepisode patients are likely to be less prone to
the effects of cognitive distortion than are symptomatic
patients. However, euthymic patients are not necessarily
asymptomatic as many have mild sub-syndromal symp-
toms, and several studies in this review will demonstrate
that even residual depressive symptoms can be strongly
associated with impaired QoL. The relationship between
QoL and hypo/mania is less well understood. Both mania
and hypomania can be associated with substantial depres-
sive symptomatology, either in the form of 'dysphoric
mania/hypomania' or when the patient experiences a
mixed episode. This understanding led Vojta and col-
leagues to hypothesize that patients with manic symp-
toms would report significantly lower QoL than would
patients who were euthymic [36]. To test this theory, the
authors administered two brief self-report measures (the
SF-12 and the EuroQoL visual analog scale) in bipolar
patients with mania/hypomania (N = 16), MDD (N = 26),
mixed mania/hypomania and depression (N = 14) or who
were euthymic (N = 30). In keeping with their hypothesis,
patients with mania/hypomania did show significantly
lower SF-12 mental health scores than euthymic patients,
with depressed or mixed patients showing significantly
poorer HRQOL again. Mean EuroQoL scores ran in the
same direction, although the difference between euthymic
and manic/hypomanic patients was not significant.H
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Table 2: Summary of studies using the SF-36 to assess quality of life in patients with bipolar disorder1
Study Patient population Physical Social Role 
physical
Role 
emotional
Pain Mental 
health
General 
health
Vitality
Arnold (2000) 44 BD outpatients 78.8 ± 22.4 57.9 ± 27.7 63.1 ± 41.6 38.6 ± 43.1 64.9 ± 25.7 55.3 ± 23.8 61.9 ± 25.4 43.6 ± 24.3
Have (2002)2 93 BD type I
43 BD NOS
89.6
91.2
73.6
80.8
77.6
81.7
69.5
80.6
74.1
82.5
62.3
68.7
62.6
68.2
58.0
62.0
Leidy (1998) 34 euthymic
28 depressed
84.4 ± 20.2
72.2 ± 28.3
73.2 ± 18.2
29.3 ± 20.0
86.2 ± 28.0
32.3 ± 38.6
76.2 ± 31.2
8.3 ± 20.3
59.6 ± 29.0
54.7 ± 25.3
69.2 ± 17.9
33.4 ± 16.5
70.9 ± 20.7
58.0 ± 21.2
52.0 ± 16.2
20.4 ± 17.5
Namjoshi (2002) 122 BD type I (manic/mixed) 65 olanzapine 57 
placebo
86.8 ± 16.8
84.5 ± 21.9
47.1 ± 28.3
46.0 ± 31.8
70.4 ± 40.2
65.4 ± 40.3
37.4 ± 42.3
36.3 ± 43.3
68.4 ± 26.4
61.7 ± 25.0
59.9 ± 22.6
58.5 ± 19.8
69.0 ± 22.7
65.2 ± 24.3
63.3 ± 24.0
66.6 ± 20.0
Patelis-Siotis (2001) 34 BD CBT completers
8 BD CBT non-completers
80.4 ± 19.3
63.8 ± 30.6
58.1 ± 25.0
46.9 ± 28.1
41.2 ± 39.8
40.6 ± 44.2
17.6 ± 33.1
29.2 ± 41.5
68.5 ± 23.7
63.4 ± 27.0
52.4 ± 18.0
44.0 ± 22.0
66.6 ± 21.7
46.4 ± 29.6
39.4 ± 19.3
28.1 ± 21.4
Revicki (1997) 14 BD patients (in-person)
14 BD patients (by telephone)
78.4 ± 25.2
77.0 ± 29.3
53.6 ± 30.2
57.1 ± 29.9
65.2 ± 38.7
59.8 ± 41.0
40.5 ± 42.9
33.3 ± 40.6
68.0 ± 31.8
69.3 ± 28.2
53.4 ± 22.8
53.9 ± 20.0
59.8 ± 22.8
57.5 ± 22.7
41.4 ± 18.7
41.4 ± 20.5
Tsevat (2000) 53 BD patients 78.7 ± 23.4 58.7 ± 27.9 63.2 ± 40.9 38.9 ± 42.3 65.3 ± 26.0 56.2 ± 23.7 62.1 ± 24.3 45.4 ± 24.4
Shi (2002) 453 BD type I
234 olanzapine 219 haloperidol
85.2 ± 23.2
90.5 ± 15.7
61.1 ± 31.8
61.2 ± 29.1
66.1 ± 39.6
72.8 ± 36.3
53.3 ± 43.1
50.1 ± 43.7
79.8 ± 26.2
81.2 ± 26.1
71.0 ± 20.4
72.8 ± 16.5
73.6 ± 21.8
75.1 ± 19.2
75.8 ± 19.1
80.0 ± 14.9
Shi (2004) 573 BD type I (currently depressed)
250 olanzapine
58 olanzapine/fluoxetine combination
265 placebo
65.8 ± 27.6
68.8 ± 25.0
66.6 ± 26.2
29.1 ± 20.9
30.6 ± 20.8
32.5 ± 21.4
47.8 ± 44.0
44.8 ± 41.8
46.4 ± 42.3
12.9 ± 25.4
9.8 ± 23.4
14.6 ± 28.7
60.6 ± 27.1
60.8 ± 25.6
57.8 ± 26.1
30.0 ± 16.1
31.0 ± 17.3
31.3 ± 15.7
51.1 ± 22.3
52.3 ± 20.7
48.6 ± 22.6
25.5 ± 17.5
25.3 ± 19.0
25.6 ± 17.6
Yatham (2004) 920 BD type I (currently depressed/ depressive 
episode in previous 60 days)
70.2 ± 26.2 29.9 ± 22.8 36.7 ± 40.9 11.4 ± 23.5 62.2 ± 27.1 31.0 ± 17.3 47.5 ± 23.3 22.4 ± 17.7
1 Data presented as mean ± SD
2 SDs not availableHealth and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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In the largest study to date of QoL in bipolar depression,
Yatham and colleagues have reported on SF-36 scores in
BD type I patients (N = 920) who were either currently
depressed, or had experienced a recent episode of depres-
sion [37]. SF-36 scores were remarkably low in the role-
physical, vitality, social functioning, role-emotional and
mental health sub-scales (see Table 2). The authors went
on to compare these scores with those derived from seven
large (>100 outpatients) studies of HRQOL in unipolar
depression that had also administered the SF-36. Sub-
scale scores tended to be lower in the bipolar sample than
in the unipolar sample, with the exception of the bodily
pain sub-scale, where unipolar depressives tended to
exhibit higher scores. Mean SF-36 scores were significantly
(weakly: range -0.1 to -0.3) negatively correlated with
HAM-D scores, providing some evidence for the construct
validity of the instrument in this population. Whilst this
study is robust in terms of its large sample size and well-
described clinical population, it did not control for
depression severity or demographic variables in between-
group comparisons. Furthermore, diagnosis of bipolar
disorder was made by careful clinical interview, whereas
unipolar depression was diagnosed via a number of sub-
jective and objective methods.
A study by Ozer and colleagues [38] assessed 100 interep-
isode patients with BD in Turkey with the aim of examin-
ing the impact of 'history of illness' and 'present
symptomatology' factors upon a variety of outcome meas-
ures including the Schedule for Affective Disorder and
Schizophrenia (SADS) and Quality of Life Enjoyment and
Satisfaction Questionnaire (Q-LES-Q) [39]. The Q-LES-Q
is a 93-item self-report measure of the degree of enjoy-
ment and satisfaction in various areas of daily living. The
questionnaire was developed and validated for use in
depressed outpatients and has eight summary scales that
reflect major areas of functioning: physical health, mood,
leisure time activities, social relationships, general activi-
ties, work, household duties and school/coursework.
Mean Q-LES-Q scores can be derived from the eight sum-
mary scales and range from 0–100, where higher scores
indicate better QoL. Using multivariate analysis, Ozer and
colleagues found that none of the historical variables
(including age at first episode, number of previous depres-
sive/manic episodes, duration of illness, number of hospi-
talizations, age at first hospitalization, or number of
symptoms during first episode) were predictive of mean
Q-LES-Q scores. Of the current symptoms assessed, only
the depression subscale of the SADS interview signifi-
cantly predicted lower Q-LES-Q scores, accounting for
only 13% of the observed variance. When the patient pop-
ulation was subdivided into three groups (low, moderate
and high) according to severity of SADS depression scores,
mean Q-LES-Q scores were 39%, 38% and 35%, respec-
tively. In comparison, mean Q-LES-Q scores have been
reported to be 42% in hospitalized psychiatric inpatients
[40], 42% in outpatients with MDD [41], 44% in patients
with seasonal affective disorder (SAD) [41], 53% in
patients with chronic MDD [42], and 83% in the general
population (Rapaport, personal communication).
Ruggeri and colleagues [43] investigated the relationship
between QoL and a variety of clinical and demographic
variables in a community-based sample of patients (N =
268) with mixed psychiatric diagnoses, 22 of whom were
bipolar. QoL was assessed via the Lancashire Quality of
Life Profile (LQOLP), which assesses perceived well-being
and functioning in 9 major life domains on a 7-point Lik-
ert scale (where higher scores indicate better QoL). We
extracted LQOLP results for the bipolar sample from data
provided by the authors, finding that mean satisfaction
scores for the 9 domains were 4.4 ± 1.0, a score similar to
that reported for the entire patient sample. In another
study of recently discharged Nigerian outpatients (N = 25)
with BD type I or II, World Health Organization Quality
of Life Assessment (WHO-QOL-BREF-TR) scores were
reported to be 'good' in 5 (20%) of patients, 'fair/average'
in 14 (56%) and 'poor' in 6 (24%) of patients (data by
WHOQOL-Bref domain also provided by authors during
personal communication) [44].
Finally, Perlis and colleagues have recently provided an
analysis of 'early onset' in 983 patients (BD type I, II or
NOS) enrolled in the Systematic Treatment Enhancement
Program for Bipolar Disorder (STEP-BD) [45] in which
QoL was assessed. The multicentre STEP-BD program, a
large prospective, naturalistic study than combines several
randomized-controlled trials, has selected to use the Q-
LES-Q to assess QoL and the GAF and 'Range of Impaired
Functioning Tool' (LIFE-RIFT) to measure functional sta-
tus. Perlis and colleagues provide the first report on QoL
from the project, having looked specifically at the effect of
age of onset (grouped into 'very early age, <13 years', 'early
age, 13–18 years' and 'adult, > 18 years') of mood symp-
toms in BD upon outcome. Younger age of onset was
found to be a significant predictor of Q-LES-Q scores at
study entry (where treatment and clinical status would
have varied widely between patients), but not of function-
ing as measured by the GAF or LIFE-RIFT. These results
represent early data from a study that has the potential to
address several important questions surrounding QoL in
BD.
ii) Comparisons of QoL in patients with BD with that of other patient 
populations
We identified five studies comparing QoL between
patients with BD and patients with other conditions. Two
of these used the SF-36, one used the 'Quality of Life
Index', the Q-LES-Q and the WHO-QOL-BREF and one
applied a 'health utilities' model.Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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The SF-36 [46] is currently the most widely used measure
of HRQOL [47]. The self-report questionnaire contains
eight sub-scales assessing physical functioning, social
functioning, role limitations (physical), role limitations
(emotional), pain, mental health, general health and
vitality. These yield an overall domain score on a 0–100
scale, where 0 represents worst possible health and 100
best possible health. Arnold and colleagues [48] com-
pared SF-36 scores between patients with BD (N = 44) and
chronic back pain (N = 30) with norms previously
reported for a general population sample (N = 2,474)
[49]. The results of the study indicated that HRQOL was
compromised in all SF-36 domains except physical func-
tioning in patients with BD compared with the general
population sample (see Table 2). The BD group fared bet-
ter than the back pain group in the physical, role limita-
tion (physical), pain and social domains, although no
significant differences were observed in terms of role lim-
itation (emotional) or mental health domains. While the
study provides a useful initial comparison of HRQOL
between BD and other conditions, its findings should be
interpreted with some caution owing to the disparate
sample sizes involved. It also utilized previously pub-
lished norms for the SF-36 that had been derived by dif-
ferent data collection methods.
The Netherlands Mental Health Survey and Incidence
Study (NEMESIS) has examined the epidemiology of psy-
chiatric disorders in a large general population sample
[50]. Using the Composite International Diagnostic Inter-
view (CIDI), 136 adults were identified with DSM-III-R
lifetime BD (93 with BD type I and 43 with BD NOS) and
administered the SF-36. Participants with BD showed sig-
nificantly more impairment in most of the question-
naire's domains compared with NEMESIS subjects
diagnosed with other psychiatric disorders (SF-36 scores
for the BD group are presented in Table 2). For example,
in the domain of mental health, participants with BD type
I experienced significantly lower mean scores (62.3) than
people with other mood (75.2), anxiety (74.0), substance
use (80.2) or no psychiatric disorders (85.8). BD type I
subjects also experienced significantly lower SF-36 scores
than patients with BD NOS in the domains of mental
health, role limitations (emotional), social functioning
and pain. However, there remains some controversy
about the accuracy with which the CIDI detects BD NOS,
limiting somewhat the inferences that can be made on the
basis of these sub-group results. A later analysis of a sub-
set (N = 40) of the original NEMESIS sample administered
the EuroQol: 5 Dimensions (EQ-5D) scale, which can be
used to provide health utility values [51]. Mean utility val-
ues (see below) for the sample were reported to be 0.82 ±
0.20, comparable to those observed in the general popu-
lation of the Netherlands.
Atkinson and colleagues [52] used a different measure,
the 'Quality of Life Index' [53], to assess QoL in patients
with BD (N = 37), MDD (N = 35) or schizophrenia (N =
69). The authors found that subjectively reported QoL
was lower in patients with BD and MDD than in those
with schizophrenia. Interestingly, this trend was reversed
for objectively assessed QoL, which included measures
such as medical history, health risk behaviors, educational
and financial levels and social functioning. These findings
led the authors to speculate about the validity of subjec-
tive measures of QoL, particularly in people with affective
disorders. These results were not replicated in Indian by
Chand and colleagues, who compared the QoL of patients
with BD (in remission and stabilized on lithium prophy-
laxis, N = 50) with patients with schizophrenia (N = 20)
and healthy controls (N = 20) [54]. Using the Q-LES-Q
and the WHOQOL-BREF, the authors found that the
bipolar group reported significantly better QoL than the
schizophrenia group in all domains of the Q-LES-Q, and
in general well-being, physical health and psychological
health on the WHO scale. Surprisingly, the authors also
observed that perceived QoL was equivalent between
patients with BD and healthy controls, with the exception
of the Q-LES-Q leisure domain, where the patient group
actually reported better functioning. Having said this,
mean Q-LES-Q scores for this particular control group
were unusually low (approximately 47%, where general
population norms for the United States are around 83%,
Rapaport, personal communication).
Although a growing number of studies have now evalu-
ated the 'health utilities' and 'health preferences' of
patients with physical conditions, relatively few have
examined these values in patients with mental illnesses,
including BD. The concept of health utility refers to an
individual's preferences for different health states under
conditions of uncertainty. Health preferences are values
that reflect an individual's level of subjective satisfaction,
distress or desirability associated with various health con-
ditions. Health utility and preferences are frequently
assessed by the 'time tradeoff' (TTO) and 'standard gam-
ble' (SG) approaches [55]. TTO refers to the years of life a
person is willing to exchange for perfect health. For exam-
ple, patients might be asked to imagine that a treatment
exists that would allow them to live in perfect physical
and mental health, but reduces their life expectancy. They
might then be asked to indicate how much time they
would give up for a treatment that would permit them to
live in perfect health, if they had ten years to live. SG refers
to the required chance for successful outcome to accept a
treatment that could result in either immediate death or
perfect health. For example, patients might be asked to
imagine that they had ten years to live in their current state
of health, and that a treatment existed that could either
give them perfect health, or kill them immediately.Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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Patients might then be asked to indicate what chance of
success the treatment would have to have before they
would accept it. Health utility and preference values are
frequently expressed as a score of 0 to 1, with higher val-
ues representing better health.
We identified one study comparing health utility in
patients with BD with other patient populations. Wells
and colleagues (1999) [56] assessed functioning and util-
ity in patients with depression or chronic medical condi-
tions within seven managed care organizations in the
United States. HRQOL was assessed via the global mental
and physical scales of the SF-12 and utility was measured
via TTO and SG. Patients with depression were catego-
rized as those with BD (N = 331), 12-month MDD (N =
3479), 12-month double depression (N = 944), 12-
month dysthymia (N = 151) or brief subthreshold depres-
sive symptoms (N = 987). In terms of HRQOL, the bipolar
group showed levels of impairment second only to
patients with double depression. Utility was also lower in
the bipolar group compared with patients with MDD, dys-
thymia or brief depressive symptoms, although not dou-
ble depression. In terms of health utility, bipolar patients
were willing to give up on average 17% of their life expect-
ancy in return for perfect health, and would accept on
average an 11% risk of death in exchange for perfect
health. In comparison, patients with MDD were willing to
give up 11% of their life expectancy, and accept a 6% risk
of death.
iii) QoL instrument evaluation in patients with BD
We identified five studies that had evaluated different
QoL instruments in BD populations and one study that
examined the effects of mode of questionnaire adminis-
tration. The first of these examined the application of the
aforementioned health utility approach. The second
assessed the psychometric properties of the Lehman Qual-
ify of Life Interview (QOLI) in a heterogeneous sample of
psychiatric inpatients. The third evaluated four QoL scales
in a smaller sample of Patients with BD, while the fourth
assessed the MOS SF-12 in a large population of patients
with severe mental illness. The fifth study evaluated the
properties of the Q-LES-Q and the LQOLP in a sample of
Israeli patients with severe mental disorders. The final
study we identified examined telephone versus in-person
health status assessment in outpatients with BD.
Tsevat and colleagues (2000) [57] examined functional
status and health utility in 53 outpatients with BD
recruited from one site of the multicenter Stanley Founda-
tion Bipolar Network study. The authors aimed to assess
how patients with BD rated their current overall health
versus their current mental health, and to determine the
extent to which health utility correlated with disease state.
TTO scores for current overall health were 0.71, but were
significantly higher than scores for current mental health,
which averaged 0.61. In other words, patients with BD
were willing to give up on average 39% of their life expect-
ancy in return for perfect mental health. These values are
similar to TTO values obtained in the Beaver Dam Health
Outcomes Study in patients with depression (0.70) or
anxiety (0.77). SG scores were not significantly different
for overall health (0.77) and mental health (0.70). SF-36
scores for the study are presented in Table 2. Certain SF-36
domains (general health, vitality and role-emotional)
were significantly correlated with mental health TTO and
SG scores, but levels of mania were not correlated with
utilities for either overall health or mental health. The
authors concluded that health utilities may be related to
certain health status attributes and to level of depression,
but may not be related to level of mania in patients with
BD. One advantage of the health utility/preference
approach to QoL assessment is that it allows the calcula-
tion of quality-adjusted life years (QALYs). QALYs are a
commonly used outcome measure in cost-effectiveness
studies, but our literature search did not find any studies
that had calculated QALYs for BD populations.
Russo and colleagues [58] performed a rigorous psycho-
metric evaluation of the QOLI [59] in a large sample (N =
981) of acutely ill hospitalized psychiatric inpatients. Of
these, 138 were diagnosed according to DSM-III-R criteria
with bipolar depression, 103 with acute mania and the
remainder with unipolar depression, schizophrenia, or
'other' diagnoses. The QOLI contains 44 items and 7 sat-
isfaction scales, a global satisfaction item and 14 func-
tional items, with all satisfaction scores ranging from 1
(terrible) to 7 (delighted). Patients were administered the
instrument using a structured interview procedure within
48 hours of admission and discharge. While the QOLI was
successfully completed by 90% of patients overall, rates
did vary according to patient diagnoses with non-comple-
tion rates being lowest in patients with bipolar depression
(12%) and highest in manic patients (31%). Reasons
given for non-completion of the measure varied, the most
common being 'inadequate staff time' (39%), 'patient too
psychotic, demented, or confused' (13%), or 'too agitated
or sleepy' (12%). The QOLI showed good psychometric
properties overall, although there was some concern
about an apparent lack of construct consistency (low cor-
relations between satisfaction and functional measures)
in patients with mania. Analysis of QOLI sub-scales
showed that, broadly speaking, manic patients reported
the highest levels of satisfaction and function, with bipo-
lar and unipolar depressed patients reporting the lowest
levels.
Leidy and colleagues [60] examined the psychometric
properties of four QoL measures in 62 BD type I patients
(34 euthymic, 28 depressed). Patients completed the SF-Health and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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36, the Quality of Life in Depression Scale (QLDS), the
Mental Health Index 17 (MHI-17) and the MOS Cognitive
Function Scale (CFS). The study provided further evidence
that both euthymic and depressed patients with BD are
capable of providing subjective reports of their HRQOL.
Baseline SF-36 scores were markedly impaired in the
depressed sub-group, with the vitality, social and role lim-
itation (emotional) domains all falling below the 25th
percentile (see Table 2). QoL as measured by the QLDS
was poorer than has been reported elsewhere for patients
with unipolar depression. Cronbach's alpha scores for the
QLDS, MHI-17, CFS and four of the eight SF-36 sub-scales
(physical functioning, role physical, vitality and metal
health) all fell above the generally accepted level of 0.80.
Test-retest reliability for the scales were modest (intraclass
correlations ranged between 0.18 on the SF-36 role emo-
tional scale and 0.80 for physical functioning), although
the reliability of the scales was assessed over an unusually
long time period (8 weeks). Scores on the QLDS, MHI-17
and CFS were significantly correlated with patients' Ham-
D scores, as were several of the SF-36 sub-scales, thus con-
firming the construct validity of the scales in patients with
BD. Finally, the MHI-17, CFS, QLDS and SF-36 vitality,
role emotional and mental health sub-scales were shown
to be responsive to change in depression status over time;
the QLDS has recently been successfully used as an out-
come measure in a large pharmaceutical treatment trial
(Shi et al., 2004, see section IV).
Salyers and colleagues [61] conducted a psychometric
evaluation of another MOS instrument, the SF-12 [62], in
a sample of 946 patients with severe mental illness, 164 of
whom were diagnosed with BD. Mean (± SD) SF-12 phys-
ical functioning and mental functioning scores for the
bipolar group were 46.1 ± 11.5 and 39.6 ± 12.7 respec-
tively, although mental health functioning scores were
significantly lower (31.8 ± 13.4) in patients with unipolar
MDD. The instrument showed acceptable levels of relia-
bility and validity in the entire sample, although it is
worth noting that is was administered by trained inter-
viewers, rather than as a self-report measure.
Ritsner and colleagues [63,64] have compared responses
on the Q-LES-Q and the LQOLP in a sample of 175 non-
clinical controls and 199 Israeli patients with severe men-
tal illness (SMI), 17 of whom were diagnosed with BD. In
personal communication with the authors, we were
informed that mean Q-LES-Q scores for the manic,
depressed and mixed sub-groups of Patients with BD in
the study were 40%, 25% and 33% respectively. Both
instruments showed generally acceptable levels of internal
consistency, test-retest reliability and criterion validity (in
the entire patient population) but notably low levels of
convergent validity between the instruments' domains,
particularly in the control group. Finally, Revicki and col-
leagues (1997) [65] examined the effects of administering
the SF-36 either in person or by telephone in 28 patients
with BD (see Table 2). SF-36 domain scores were not sig-
nificantly affected by mode of administration.
iv) Studies using QoL instruments to assess outcome in patients with 
BD
We identified eight studies that had used a QoL measure
to assess outcome in BD populations: five clinical trials
that examined pharmacological interventions for the dis-
order and three studies that assessed non-pharmacologi-
cal interventions.
Namjoshi and colleagues from a Lilly research group have
conducted a series of studies examining the impact of
treatment with olanzapine upon QoL [66-70]. In the first,
Namjoshi et al., (2002) evaluated the impact of acute (3-
week) treatment with olanzapine or placebo and long-
term (49-week open label) treatment of BD type I (manic/
mixed). Baseline SF-36 scores for the olanzapine and pla-
cebo group are shown in Table 2. During acute-phase
treatment, a significant improvement was observed in the
physical functioning domain of the SF-36 in the olanzap-
ine group. During the open label treatment period, how-
ever, the SF-36 bodily pain, vitality, general health and
social functioning domains showed significant improve-
ments over time. This may indicate that olanzapine has a
relatively rapid effect in terms of improving physical func-
tioning in patients with acute mania, but that treatment
may be required for longer periods for functioning to
improve in other QoL domains.
Shi and colleagues have also compared the treatment
effects of olanzapine and haloperidol in patients with
acute mania (N = 453) [67,68] weeks of acute-phase treat-
ment, significantly greater improvement in five of the SF-
36 domains (general health, physical functioning, role
limitations – physical, social functioning and vitality) was
apparent in the olanzapine group. Superiority of olanzap-
ine over haloperidol persisted over the study's 6-week
continuation phase, with concomitant improvements in
work and household functioning. Baseline SF-36 scores
for the olanzapine and haloperidol groups are shown in
Table 2. A further study examined the effects of adding
olanzapine to lithium or valproate in patients with BD (N
= 224) [69]. Olanzapine cotherapy was associated with
better outcome in several QOLI domains compared to
monotherapy with lithium or valproate alone. The SF-36
and QLDS have been used in a study comparing the ben-
efits of olanzapine alone versus an olanzapine-fluoxetine
combination or placebo [70]. Compared with placebo,
patients who received olanzapine showed greater
improvement at 8 weeks in SF-36 mental health summary
scores, and in mental health, role-emotional and social
functioning domain scores (SF-36 scores summarized inHealth and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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Table 2). The combination group fared significantly better
in terms of HRQOL improvement than the olanzapine-
alone group, showing improvement in 5 of the SF-36
domain scores and in QLDS total score. The authors also
performed a psychometric evaluation of the QLDS (see
section III).
Finally, the Q-LES-Q has been administered at baseline
(hospital discharge), 6 and 12 weeks in a comparison of
divalproex sodium and olanzapine in the treatment of
acute mania [71]. No significant treatment effects were
detected in Q-LES-Q scores in the study, although only 52
(43%) of the 120 patients randomized to either dival-
proex or olanzapine completed the QoL instrument.
Interestingly, the authors reported an association between
weight gain being reported as an adverse event and poorer
change scores in the physical, leisure, and general activi-
ties domains of the Q-LES-Q at 6 weeks (but not at 12
weeks). Negative correlations were reported between
increased weight (at 6 weeks) and overall life satisfaction,
physical health, mood, general activities and satisfaction
with medication on the Q-LES-Q.
Although current recommendations favor the use of phar-
macological treatments such as lithium and mood stabi-
lizers in the initial treatment and symptom control of BD,
there is increasing recognition of the role of psychother-
apy in the management of the disorder. We identified one
study that had used a QoL tool to assess outcome follow-
ing a psychotherapy intervention for BD. Patelis-Siotis
and colleagues [72] used the SF-36 in a feasibility study of
group cognitive behavior therapy (CBT) in patients with
BD. Although baseline SF-36 data was available for 42
patients (see Table 2), pre and post intervention data was
only available for a proportion of participants (N = 22) as
completion of the QoL questionnaires was optional. Nev-
ertheless, SF-36 vitality and role emotional scores were
significantly improved following CBT, with an accompa-
nying trend towards improved social functioning.
Another study we identified specifically examined the
effects of vocational rehabilitation upon outcome in 149
patients with SMI, 21 of whom were diagnosed with bipo-
lar disorder [73]. In personal communication with the
authors, we learned that mean (± SD, range 1–7 where
higher scores indicate better QoL) baseline QOLI 'overall
life satisfaction' scores were 4.7 ± 1.1, with 'general satis-
faction' domain scores of 4.9 ± 1.3. Although outcome
data was not available specifically for the bipolar group,
better QoL outcomes were associated with 'competitive
work activity' in the overall sample compared to other
reduced forms of work activity. Finally, a recent study has
examined the effects of providing 3 sessions of psychoed-
ucation about lithium treatment to patients (N = 26) with
BD [74]. In addition to assessing the effects of psychoed-
ucation upon medication adherence, the authors exam-
ined the impact of education upon QoL, as measured by
the WHO-QOL-BREF. Following psychoeducation,
patients in the intervention arm of the study showed sig-
nificant improvement in 2 of the WHOQOL BREF's 4
domains (physical health and social functioning) and in
overall perceived health. Patients in the control arm of the
study, in comparison, showed no significant changes in
their perceived QoL. The results of the study indicate that
it may be possible to alter patients' perceptions of their
QoL even with relatively brief psychological interven-
tions.
Discussion
Prior to 1999, only 10 studies had systematically
addressed the measurement of HRQOL in patients with
bipolar disorder [10]. A second review of studies that had
examined HRQOL in BD prior to 2004 identified 65 stud-
ies [9]. We conducted a subsequent review of studies
examining generic and HRQOL in bipolar disorder that
had been published prior to November 2004. Our litera-
ture search identified 28 studies in total, 7 (25%) of which
were published before 1999 (there is discrepancy in the
number of studies identified prior to 1999 between the
two reviews due to differing inclusion criteria). The
remaining 21 (75%) were published between 2000 and
2004, indicating that there is developing interest in this
field of research. The studies we identified were quite het-
erogeneous in nature. Several undertook to assess QoL
during different phases of the disorder, for example, cross-
sectional research that compared perceived QoL in
euthymic, manic or depressed patients with BD. Other
studies compared QoL in bipolar samples to that of other
patient populations, both with other psychiatric disorders
and with chronic physical conditions. Another vein of
research examined the psychometric properties of a vari-
ety of generic and HRQOL instruments in BD popula-
tions. Finally, we identified several studies that had used a
QoL instrument to assess outcome in trials of pharmaco-
logical and non-pharmacological treatment inventions
for the condition.
The studies were also of variable scientific quality. Meth-
odological shortcomings included small sample sizes,
cross-sectional designs, idiosyncratic diagnostic methods
or undifferentiated diagnostic groups, and use of inappro-
priate or poorly validated QoL instruments. This being
said, the overall scientific quality of research in this field
does appear to be improving. Of the 10 studies identified
in the review by Namjoshi and colleagues, only one pos-
sessed a sample of size of more than 100 patients with BD.
In comparison, we identified eleven studies that had
enrolled more than 100 patients. It was particularly
encouraging to see that some of the large pharmacological
trials of treatment interventions for BD are now using QoL
measures as secondary outcome measures. Clinical trialsHealth and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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in bipolar populations have traditionally used objectively
rated measures such as rates of relapse, hospitalization or
symptom reduction to assess patient outcome. However,
the concomitant use of QoL indices does appear to pay
dividends. For example, Namjoshi and colleagues [66]
found that the timing of response to treatment with olan-
zapine differed in terms of symptomatic and QoL out-
come. Symptom reduction in the olanzapine group
occurred relatively quickly, with patients showing a 10-
point decrease in Young Mania Rating Scale (YMRS)
scores during the study's 3-week acute treatment phase.
Improvements in SF-36 scores, however, occurred more
slowly. Only the domain of physical functioning showed
significant improvement by the end of the acute treatment
phase, whereas it was the domains of social functioning,
general health, vitality and bodily pain that were signifi-
cantly improved at the end of the 49-week maintenance
phase. These findings are in accordance with other
research showing that 98% of first episode mania patients
achieve syndromal recovery after 24 months, but only
38% achieve functional recovery [75]. Sole reliance on
symptomatic outcome measures may not detect these
more subtle changes in well-being, functioning and QoL.
Although there appears to be increasing use of QoL meas-
ures in pharmacological research in bipolar populations,
we identified surprisingly few studies of psychological
interventions that had incorporated a QoL assessment. In
a review of psychosocial interventions for BD, Huxley and
colleagues (2000) [76] identified 32 peer-reviewed
reports examining group, couple/family or individual psy-
chotherapy in BD, none of which systematically assessed
QoL. Our own review only identified one relevant publi-
cation, a feasibility study of group CBT which incorpo-
rated the SF-36 [72]. As Huxley and colleagues note,
future research in this area should employ much broader
measures of outcome, such as the assessment of QoL,
which may be less amenable to pharmacological treat-
ment in isolation.
An important general conclusion from this review is that
the measurement of QoL is feasible in some patients with
BD. However, there remains a paucity of information
about the ability of patients in the hypo/manic phase of
their illness to reliably and accurately complete QoL
measures. One of the more rigorous studies to date was
performed by Russo and colleagues (1997) [58], in which
nurses administered the QOLI via a structured interview
procedure to 103 patients with acute mania. Completion
rates for the questionnaire were 69% in acutely manic
patients, compared to 88% in bipolar depressed patients.
In the Namjoshi et al., [66] study of olanzapine in
patients with acute mania, SF-36 scores were successfully
obtained for 122 of 139 (88%) of patients who entered
the study's randomization phase. In the smaller study by
Vojta and colleagues [36], two brief QoL instruments were
successfully completed by 16 patients with mania/hypo-
mania. More research is needed to ascertain how feasible
it is to administer self-report measures of QoL in patients
with hypo/mania, although other research in bipolar pop-
ulations has indicated that patients with mild to moderate
manic symptoms can provide reliable descriptions of their
symptoms [77]. Although there is controversy about the
validity of the technique, [78] proxy measures of QoL can
be obtained from family members or clinicians, and may
offer one solution to this problem. Additional research is
also needed to determine the longitudinal course of QoL
in patients with BD. The majority of the studies we identi-
fied were cross-sectional in nature. Useful future research
would longitudinally follow the course of QoL in a cohort
of patients with BD as they experienced different phases of
the illness. Research is also required in first-episode mania
patients to help elucidate the relationship between length
of illness, episode frequency and QoL.
The studies we identified were also heterogeneous in
terms of the QoL instruments they incorporated. By far
the most frequently utilized were the MOS range of
HRQOL measures; 16 of the 28 studies we identified
(57%) utilized the SF-12, SF-20 or the SF-36. The results
of studies using the SF-36 were amalgamated in Table 2.
Inspection of these data indicates that, in general, physical
functioning appears to be relatively good in patients with
BD (range 63.8 – 91.2). Mental health scores are unsur-
prisingly much lower (range 30.0 – 72.8). In comparison,
SF-36 mental health functioning scores have been
reported to be 40.0 (± 17.5) in primary care patients (N =
536) initiating treatment for depression [79]. However, it
remains difficult to make any broad generalizations on
the basis of this grouped data owing to differences in
patient populations, recruitment methods and sample
sizes that result in wide ranges of scores in some domains.
Given the breadth of existing data for the SF-36 in bipolar
populations, the scale's acceptable psychometric proper-
ties and detailed normative data, we recommend this
scale for the measurement of health-related QoL in
patients with BD. The WHO-QOL-BREF is an alternative
that has undergone rigorous international development
and is available in a wide variety of languages.
A number of other QoL instruments have been utilized in
bipolar populations, including the Illness Intrusiveness
Rating Scale (IIRS), the Quality of Life Enjoyment and Sat-
isfaction Questionnaire (Q-LES-Q), the Lehman Quality
of Life Interview (QOLI), the WHO-QOL-BREF and the
health utility time tradeoff (TTO) and standard gamble
(SG) approaches. However, only a small number of the
studies we identified reported on the psychometric prop-
erties of these instruments, and it remains the case that
few measures of QoL have been appropriately evaluatedHealth and Quality of Life Outcomes 2005, 3:72 http://www.hqlo.com/content/3/1/72
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for use in BD populations. Some of these instruments are
semi disease-targeted in the sense that they have been
developed in and for depressed populations (i.e. the Q-
LES-Q and QLDS). Both the Q-LES-Q and QLDS appear to
possess acceptable psychometric properties and, impor-
tantly, are responsive to change in response to both psy-
chological and pharmacological treatment interventions
and can be recommended here for use in bipolar popula-
tions.
There is at present no QoL measure specifically designed
for use in bipolar populations. Although existing QoL
instruments are likely to capture key aspects of QoL, they
may be insensitive to some of the unique problems posed
by this complex psychiatric condition. For example, few
QoL instruments designed for use in psychiatric popula-
tions assess routine, independence, spirituality or stigma,
which have been sown to have particular bearing upon
QoL in patients with BD [80]. Bipolar disorder is also
unique in that it can be characterized by a variety of mood
states, including hypo/mania, depression or mixed states.
The understanding that mania can also be associated with
depressive symptoms, and that patients will experience
periods when they are relatively euthymic, complicates
the assessment of QoL in this population. We suggest that
an important step forward in this field of research would
be made with the development of a disease-specific QoL
instrument for BD. We believe that such an instrument
would need to have a number of qualities. It would have
to work effectively in the depressed, hypo/manic, mixed
and euthymic phases of BD. It would need to be concise
enough not to put overdue response burden on the
patient, but detailed enough to tap into the major areas of
well-being affected by the disorder. The relevance of the
scale would need to be ensured by thorough consultation
with patients, their families and their clinicians. This proc-
ess should involve individual qualitative interviews and
focus group work with patients with BD and their family
members at different stages of the disorder, and consulta-
tion with psychiatrists, mental health workers, and pub-
lic-sector organizations. It would be useful if the
instrument was available in self-report, interviewer-
administered and proxy-respondent formats to provide
alternative methods of administration in acutely manic
populations. Finally, the psychometric properties of the
instrument would need to be carefully evaluated in terms
of reliability, validity, responsiveness and other standard
psychometric assessments.
Conclusion
In recent years, major developments in the pharmacolog-
ical control of bipolar disorder have occurred. One result
of these improvements has been that some patients will
BD now experience fewer side effects and less physical
symptomatology, allowing the focus to shift to other con-
cerns, including improving inter-episode functioning and
perceived quality of life. Our review found that there is
growing interest in characterizing QoL in bipolar disorder
populations, and determining the impact of treatment
interventions upon life quality. The scientific quality of
research in this field has been variable, but increasing
numbers of studies of good design are now being con-
ducted. We highlighted several important avenues for
future research, including the need for assessments of QoL
in first episode and hypo/manic patients, more well-
designed longitudinal research and research into the
impact of psychosocial interventions upon QoL, and the
development of a disease-specific measure for use in bipo-
lar populations. Bipolar disorder creates a major health
concern, both for the individual and for society, and more
information is still needed about the impact of the condi-
tion upon QoL. Such information may then bring us one
step closer towards developing treatment regimens that
maximize both symptom reduction and quality of life for
patients with this complex condition.
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